UroGen Pharma Ltd. is launching its first commercial drug following the US Food and Drug Administration approval of Jelmyto (mitomycin) for adults with low-grade upper tract urothelial cancer (LG UTUC). The company announced the approval after market close on 15 April and said it will aim to launch the drug on 1 June despite the ongoing COVID-19 pandemic.
"None of us could have anticipated that we would be executing a launch in the middle of a pandemic," CEO...